Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

• Váldodahkkit: Vergnenègre A (Dahkki), Ray JA (Dahkki), Chouaid C (Dahkki), Grossi F (Dahkki), Bischoff HG (Dahkki), Heigener DF (Dahkki), Walzer S (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Dove Medical Press, 2012-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Alain Vergnenègre1, Joshua A Ray2, Christos Chouaid3, Francesco Grossi4, Helge G Bischoff5, David F Heigener6, Stefan Walzer21Department of Pneumology, Hôpital du Cluzeau, Limoges, France; 2Global Health Economics and Strategic Pricing, F Hoffmann-La Roche Ltd, Basel, Switzerlan...